Navigation Links
Researchers add new tool to tumor-treatment arsenal

A new study demonstrates the potential effectiveness of treating tumors by combining agents that damage DNA with a drug that sensitizes cancer cells to these agents.

The research, led by George Thomas, PhD, professor at the University of Cincinnati's (UC) Genome Research Institute, and Heidi Lane of Novartis Institutes for Biomedical Research, appears in the March 25, 2005, issue of the journal Cell.

Dr. Thomas and a co-author Stefano Fumagalli, PhD, began this research while working at the Friedrich Miescher Institute for Biomedical Research in Basel, Switzerland, and completed these studies at UC's Genome Research Institute, where further studies continue.

"The use of DNA-damaging agents has revolutionized chemotherapy against a wide variety of cancers," says Dr. Thomas. "However, a narrow therapeutic window, combined with possible severe side effects, has greatly limited their broader use."

These factors, says Dr. Thomas, have probably contributed to recent reports of the under-dosing of patients and the failure to blunt the disease.

When cancer cells are treated with a DNA-damaging agent, a cancer-suppressing gene known as the "guardian of the cell" (a protein called p53) responds by either killing the cell, if the damage is too severe, or allowing the cancer cell to repair the damaged DNA. If the DNA is repaired, cells can continue to multiply.

The dilemma is that high doses of DNA-damaging agents can be toxic, and doses that are too low allow for DNA repair and further cell growth. Thus, says Dr. Thomas, there is need for drugs that can sensitize cells to lower doses of DNA-damaging agents to guarantee cell death, but without the toxic side effects.

The researchers studied the results of combining a DNA-damaging agent called cisplatin with RAD001, a derivative of the immunosuppressive drug rapamycin. Used in organ transplant patients, rapamycin and its derivatives have shown promising anti-tumor activity i n phase I and II clinical trials.

RAD001 lowers the amount of DNA-damaging agent needed by blocking p53's DNA-repair function, automatically killing the cancer cells when agents like cisplatin are introduced.

"These findings provide the rationale for combining DNA-damaging agents with sensitizing agents like RAD001," says Dr. Thomas. "Since about 50 percent of all solid tumors contain p53, such a drug combination could dramatically improve the treatment of solid tumors."


'"/>

Source:University of Cincinnati


Related biology news :

1. Researchers discover way to make cells in the eye sensitive to light
2. Researchers find how protein allows insects to detect and respond to pheromones
3. Researchers Uncover Key Step In Manufacture of Memory Protein
4. Researchers reveal the infectious impact of salmon farms on wild salmon
5. Researchers identify target for cancer drugs
6. Researchers discover molecule that causes secondary stroke
7. Researchers find missing genes of ancient organism
8. Researchers trace evolution to relatively simple genetic changes
9. UF Researchers Map Bacterial Proteins That Cause Tooth Loss
10. VCU Researchers Identify Networks Of Genes Responding To Alcohol In The Brain
11. Researchers develop rapid diagnostic tool for pathogen identification
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/20/2016)... 2016 The rising popularity of mobility ... is stoking significant interest in keyless access systems. ... low energy (BLE), biometrics and near-field communication (NFC) ... of wireless technologies in the automotive industry. This ... access systems opens the market to specialist companies ...
(Date:12/19/2016)... y TORONTO , 19 de diciembre de 2016 ... Inc. que permitirá el desarrollo acelerado de MSC-1, un anticuerpo humanizado ... tipos de tumor en 2017, con múltiples sitios previstos a lo ... ... objetivo en el factor inhibidor de leucemia (LIF), una citoquina pleiotrópica ...
(Date:12/16/2016)... 16, 2016 Research and Markets has announced ... Global Forecast to 2021" report to their offering. ... The biometric vehicle access ... a CAGR of 14.06% from 2016 to 2021. The market is ... to reach 854.8 Million by 2021. The growth of the biometric ...
Breaking Biology News(10 mins):
(Date:1/24/2017)... -- According to a new market research ... (CD34, PBMC, BLT)), Application (Neuroscience, Hematopoiesis, Oncology, Immunology & ... CRO) - Global Forecast to 2021", published by MarketsandMarkets, ... for the forecast period of 2016 to 2021. This ... 2021 from USD 73.3 Million in 2016, growing at ...
(Date:1/24/2017)... - BioAmber Inc. (NYSE: BIOA ) today announced ... Rodman & Renshaw, a unit of H.C. Wainwright ... representative of several underwriters, under which the underwriters have ... minimum of 2,105,264 shares of common stock of the ... 1,052,632 shares of common stock of the Company with ...
(Date:1/23/2017)... 23, 2017   Enteris BioPharma, Inc. , announced ... Sanofi to leverage Enteris, proprietary and patented ... develop an oral formulation of one of Sanofi,s preclinical ... Chief Executive Officer and Executive Chairman of Enteris BioPharma, ... the tremendous value our Peptelligence platform program offers in ...
(Date:1/23/2017)... , ... January 23, 2017 , ... ... been appointed Vice President, Preclinical Safety and Senior Director, Safety Pharmacology. Dr. ... in India. , Dr. Thomas’ career as an academic and industry preclinical ...
Breaking Biology Technology: